If You Invested in Livongo Health (LVGO)

Livongo Health, Inc. (LVGO) was a technology-enabled healthcare company that developed and operated a consumer digital health platform focused on chronic condition management. According to company disclosures, Livongo empowered people with chronic conditions to live better and healthier lives, beginning with diabetes and expanding to hypertension, weight management, diabetes prevention, and behavioral health.

Livongo traded on Nasdaq under the ticker symbol LVGO and is classified in the Technology Services sector within the packaged software industry. The company was founded on October 16, 2008 and is headquartered in Mountain View, California. Its business combined software, data science, and connected health capabilities to support individuals living with chronic conditions and the organizations that sponsor their care.

Business focus and chronic condition programs

Livongo described itself as an Applied Health Signals company. Its platform aggregated and interpreted substantial amounts of health data and information to create actionable, personalized, and timely health signals delivered to members. These signals were intended to make it easier for people with chronic conditions to stay healthy and to improve both clinical and financial outcomes.

The company offered multiple chronic condition programs, including:

• Livongo for Diabetes
• Livongo for Hypertension
• Livongo for Prediabetes and Weight Management
• Livongo for Behavioral Health by myStrength

These offerings reflected a whole-person approach to care, with a focus on supporting members across several related conditions rather than addressing a single diagnosis in isolation.

Digital health platform and Applied Health Signals

Livongo’s consumer digital health platform was built around what it termed Applied Health Signals. Using what it called its AI+AI engine, Livongo’s team of data scientists aggregated and interpreted large volumes of health data to generate clinically based insights. These insights were delivered to members when and where they were needed, with the goal of recommending next-best actions and making day-to-day self-management more practical.

The company stated that this approach enabled a different and better experience for people with chronic conditions, and that clients adopted its platform to pursue better clinical outcomes and potential cost improvements. Livongo reported that its solutions and underlying data science platform supported remote monitoring and consumer-directed virtual care models.

Clients and market reach

Livongo’s clients included employers, health plans, health systems, government organizations, and labor unions. Company communications noted that, as of early August 2020, Livongo had more than 1,300 clients and that these clients included more than 30 percent of Fortune 500 companies and four of the top seven health plans. The company also referenced reseller and partnership relationships, including arrangements with organizations such as Teladoc Health, Fresenius Medical Care North America for chronic kidney disease, and Magellan Health for behavioral health.

Livongo’s model centered on working with these institutional clients to enroll members into its chronic condition programs. The company reported hundreds of thousands of enrolled Livongo for Diabetes members and highlighted growth in both member counts and client counts in its financial communications.

Financial reporting and growth indicators

As a publicly traded company, Livongo released quarterly financial results that included revenue, gross margin, net income or loss, adjusted EBITDA, and key operating metrics. For example, in its second and third quarter 2020 releases, the company reported year-over-year revenue growth and increases in enrolled Livongo for Diabetes members and total clients. It also disclosed an internal metric called Estimated Value of Agreements (EVA), defined as the estimated value of agreements signed in a quarter with new clients or expansions with existing clients.

Livongo emphasized that adoption of its Applied Health Signals platform and consumer-directed virtual care model contributed to its reported financial and operating trends. The company also provided reconciliations of non-GAAP financial measures and described why management used these measures alongside GAAP results.

Relationship with Teladoc Health and corporate status

In 2020, Livongo and Teladoc Health announced a planned merger agreement intended to create what they described as a global leader in consumer-centered virtual care. Company communications referenced a joint proxy statement/prospectus filed with the U.S. Securities and Exchange Commission in connection with this proposed transaction. Livongo’s earnings and investor conference announcements during that period noted the pending transaction and, in some cases, indicated that executives from both companies would present together.

Livongo’s third quarter 2020 financial release stated that the company believed joining with Teladoc Health would build on Livongo’s success and accelerate its mission. These materials discussed expected benefits of the combination in the context of forward-looking statements. While the news and disclosures describe a planned merger and related regulatory filings, the information provided here does not include a specific SEC delisting notice or a completed-transaction date for LVGO, so this page should be understood as a historical overview of Livongo as it was represented under the LVGO symbol.

Industry context and positioning

Within the technology services and packaged software landscape, Livongo occupied a niche at the intersection of digital health, chronic disease management, and virtual care. Its communications highlighted the use of connected devices, data science, and virtual interactions to support people living with chronic conditions, and positioned its Applied Health Signals approach as a way to meet individuals where they are in their health journey.

The company’s narrative emphasized consumer-centered virtual care, remote monitoring, and whole-person support. It framed its offerings as tools for employers, health plans, and other organizations seeking to address chronic conditions at scale through technology-enabled programs.

Use of this overview

This overview summarizes information drawn from Livongo’s own descriptions, financial releases, and related investor communications while LVGO was an active Nasdaq ticker. Because no recent SEC filings are included in the data above, investors and researchers should treat this as a historical profile of Livongo Health, Inc. under the LVGO symbol, rather than as a source of current corporate or trading status.